Pipeline Discovery Pre-clinical Studies Phase Ⅰ Studies Phase Ⅱ Studies Phase Ⅲ Studies NDA / BLA Market
VRC07-523LS

VRC07-523LS

VRC07-523LS is the new generation of highly potent and broadly neutralizing HIV-1 antibody, which is derived from VRC07, a heavy chain somatic variant of the broadly neutralizing antibody VRC01 from HIV+ patient. Like the progenitor antibody VRC07 and VRC01, VRC07-523LS targets the CD4 binding site on the HIV-1 envelope glycoprotein gp120 [1].  In vivo and in vitro studies showed that monoclonal antibody (mAb) VRC07, particularly its variant VRC07-523-LS, neutralized 96% of cross-clades viruses tested and was 5-8 times more potent than VRC01, and protected macaques against SHIV challenge at a 5-fold lower concentration than VRC01 in protecting macaques passively transferred with MAb prior to SHIV challenge, and the presence of mutations in Fc displays a 2-3 fold increase in plasma half-life [1].  

In phase 1a clinical study results suggest that VRC07-523LS is safe and well tolerated at all doses (1, 5, 20 and 40 mpk) and routes (IV and SC) in healthy adults. VRC07-523LS rapidly achieved concentrations greater than 10 mg/mL following 5 mg/kg SC administration. The overall compartmental half-life (t1/2) of VRC07-523LS is currently estimated to be 33±10 days. The potent neutralizing activity, breadth, and extended half-life of VRC07-523LS make this antibody a leading candidate for inclusion in HIV-1 prevention and therapeutic strategies [2, 3].   The clinical study NCT02840474 is the head-to-head comparison study of the monoclonal antibodies VRC07-523LS and VRC01LS in HIV-infected adults and the results showed both VRC01LS and VRC07-523LS were safe and well-tolerated.  Seven days after an infusion of the antibodies, fewer than half of the people given VRC01-LS had a viral load reduction of more than 0.5 logs (a threefold reduction); but VRC07-523-LS recipients had a viral load reduction of more than 1.2 logs (a 16-fold reduction) [4, 5].

TaiMed has a non-exclusive licensing agreement of VRC07-523LS from the National Institute Allergy and Infectious Diseases (NIAID) to develop combination of VRC07-523LS and TaiMed own monoclonal HIV antibodies for treatment use. A combination therapy of VRC07-523LS and TaiMed own antibody is under evaluation and development.

References

  1. “VRC07-523 Info – Search Antibody Database” in HIV Databases operated by Triad national Security, LLC for National Nuclear Security Administration of US Department of Energy (DoE) and funded by US National Laboratory of Las Alamos, US National Institutes of Health (US-NIH), and US Department of Health and Human Services (US-HHS).
  2. “VRC 605: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS) Administered Intravenously or Subcutaneously to Healthy Adults.” Conducted and funded by National Institutes of Health Clinical Center (NIH-CC), and National Institute of Allergy and Infectious Diseases (NIAID).
  3. Martin R. Gaudinski et al., “A Phase I Dose-Escalation Study of Monoclonal Antibody VRC07-523LS in Healthy Adults.” Conference on Retroviruses and Opportunistic Infections” CROI 2018, Abstract Number: 1061 (Poster 022618).
  4. “IAS 2019: FIRST TRIAL RESULTS OF NEW IMMUNE-MODULATING DRUGS PRESENTED IN MEXICO CITY.” - EATG REPORTED
  5. Chen G et al. “Safety and virologic effect of the HIV-1 broadly neutralizing antibodies, VRC01LS or VRC07-523LS, administered to HIV-infected adults in a phase 1 clinical trial.” IAS2019 conference, Mexico City. Abstract WEAA0305LB. 2019.